.svg)
Navigating GLP-1 Dosing for Optimal Results
Finding the right dosage for any medication is essential, as everyone responds differently. This is equally true for GLP-1 medications. Our clinical team will work closely with you to determine the most suitable dose, balancing the desired effects with any side effects you may experience.
Mounjaro, for example, has three stable treatment doses: 5mg, 10mg, and 15mg. Additionally, there are intermediary doses of 2.5mg, 7.5mg, and 12.5mg, which help transition between these stable doses.
In practice, this means that treatment with Mounjaro will typically begin at 2.5mg per week for the first four weeks. If you tolerate this well and experience no significant side effects, we will generally increase the dose to 5mg from the second month. However, if you do experience side effects, we may keep you on 2.5mg for a longer period to allow your body time to adjust before increasing the dose.
Once you reach 5mg, we will usually maintain this dose for a few months unless your weight loss progress is minimal. While progress varies between individuals, a useful benchmark is a minimum weight loss of approximately 1% of your starting weight per month.
If you continue to make good progress at 5mg, we may agree that there is no need to increase the dose further. You can remain on this dose for as long as necessary. However, if progress slows, we may increase the dose to 7.5mg for a month or two before stepping up to the next stable dose of 10mg.
At this stage, we would typically maintain the 10mg dose for a few months. Together, we will keep an eye on your progress and decide whether to continue at this level or increase to the maximum dose if necessary.
Our goal is gradual and sustainable weight loss. GLP-1 treatment is not a "quick fix" but rather a long-term approach to improving your health and maintaining a healthy weight.
What happens when I reach my goal weight?
Once you achieve your target, we will work with you to determine the most appropriate dose to maintain your weight. For some, this will be the current dose, while others may step down to the next stable dose. Our clinical team will closely monitor your progress and help you find the right dosage to maintain a healthy weight and overall well-being.
Dr Matthew Noble
A new weight loss programme is gaining significant traction across the UK, drawing more than 16,000 women in just two months. SheMed, a digital health provider, is reshaping how women approach weight management by integrating scientific precision with a patient-first philosophy.
Unlike conventional dieting plans, SheMed’s approach is designed specifically for women’s unique metabolic and hormonal profiles. The programme, which includes a GLP-1-based medical intervention, aims to promote sustainable weight loss without extreme dieting or unrealistic exercise regimens.
“We understand that women’s bodies work differently, and our programme is tailored to reflect that,” said Olivia Ferro, co-founder & CEO of SheMed. “This isn’t just about weight loss—it’s about long-term health, confidence, and a fundamentally different approach to well-being.”
A Medical-Grade Approach to Weight Loss
SheMed differentiates itself by offering a medically supervised weight loss programme that combines prescription GLP-1 medications with private GP oversight. The programme’s core principles include:
- Personalised Treatment Plans – Tailored weight loss strategies based on individual metabolic needs.
- Clinical Oversight – Direct access to private GPs for medical supervision.
- A Supportive Community – A peer network providing motivation and shared experiences.
- Sustainable Health Outcomes – A focus on long-term success rather than quick fixes.
Uncovering Hidden Health Risks
As part of its commitment to responsible prescribing, SheMed introduced a mandatory blood test requirement for all patients before administering GLP-1 medications. The results of this initiative were striking: 99% of applicants exhibited undiagnosed health conditions, including high cholesterol, fatty liver, and early-stage diabetes.
Initially launched as a clinical study, the blood test requirement has now been made permanent. “This initiative has fundamentally changed how we assess weight loss patients,” said Chloe Ferro, SheMed’s co-founder and Chief Growth Officer. “Many women seeking weight loss treatment had underlying health conditions they weren’t aware of. Early detection is key to improving long-term health outcomes.”
The General Pharmaceutical Council (GPhC) has recently tightened regulations around online prescriptions for obesity medications. SheMed’s rigorous screening process places it ahead of industry standards, ensuring that only patients meeting strict medical criteria receive treatment. The company’s fixed pricing model—£159 every four weeks, with no cost increase as medication doses adjust—further differentiates it in a market where pricing structures often fluctuate unpredictably.
Regulatory Scrutiny and Industry Implications
SheMed’s stringent protocols come at a time of heightened regulatory scrutiny over the distribution of GLP-1 medications in the UK. With the rise in popularity of these drugs, regulators have moved to curb inappropriate prescribing practices. Unlike some providers, SheMed does not base eligibility solely on weight or BMI. Instead, its screening process considers broader health indicators, ensuring treatment aligns with patient safety guidelines.
“We’re not just another online pharmacy dispensing GLP-1s,” said Olivia Ferro. “We’re setting new standards for what responsible prescribing should look like.”
As the UK continues to grapple with rising obesity rates and evolving treatment protocols, SheMed’s approach offers a glimpse into the future of medically integrated digital health solutions. With a growing patient base and increasing regulatory backing for stricter prescribing practices, the company is positioned as a leader in the next phase of weight loss care.
For more information, visit www.shemed.co.uk.
SheMed, a pioneering women’s health company, has announced an extension to its ground-breaking GLP-1 clinical trial in response to an extraordinary level of interest. The entry period, which was initially scheduled to conclude by December 2024, will now run until January 31, 2025.
Co-founders Chloe and Olivia Ferro are determined to create a safer, evidence-based digital health system that prioritises the well-being of women. This extension supports their mission to address long-standing gaps in women’s healthcare research and treatment.
A Landmark Women’s Health Study
The SheMed Weight Loss Programme, a comprehensive initiative that combines weight loss support with advanced clinical research, aims to conduct the largest clinical study of UK women for GLP-1 medications to date. Historically used to treat diabetes and obesity, GLP-1 medications have untapped potential in addressing broader women’s health conditions. SheMed’s study seeks to uncover definitive evidence and actionable insights on how these medications can benefit women beyond weight management.
Through this programme, SheMed is collecting data that could revolutionise care for conditions such as Polycystic Ovary Syndrome (PCOS) and menopause. By doing so, the study hopes to not only empower women to achieve their health goals but also pave the way for significant advancements in the field of women’s health—a domain that has historically lagged behind other medical research areas.
How the SheMed Weight Loss Programme Works
The SheMed Weight Loss Programme is designed as a high-adherence care model, ensuring participants stay on track and achieve their health goals safely. Key programme features include:
- Eligibility screening: Comprehensive at-home blood tests are required to confirm initial eligibility.
- Regular monitoring: Weekly weigh-in calls, monthly questionnaires, and check-ins ensure participants’ progress and safety are closely tracked.
- Data-driven insights: All participant data is anonymised and used exclusively to further research in women’s health.
- Treatment adherence: Participants must complete live check-ins and refill questionnaires to maintain their eligibility on the programme.
The programme’s rigorous approach not only promotes individual success but also ensures the reliability of SheMed’s clinical findings.
Strict Acceptance Guidelines
To maintain the highest research standards, SheMed has implemented strict acceptance criteria for the clinical trial. Eligible participants must:
- Be adults aged 18 to 75 living in England or Wales.
- Commit to the programme’s requirements, including:some text
- Weekly weigh-in calls.
- Monthly questionnaires.
- Blood tests at the start, mid-point, and end of the programme.
The trial will be one of the most comprehensive studies ever conducted in the UK for GLP-1 medications.
Research Expectations
Participants will benefit from:
- Weight loss support: GLP-1s are expected to aid significant weight reduction and improve associated health complications such as heart disease, diabetes, and joint issues.
- Health condition insights: The study aims to identify how GLP-1 medications impact symptoms related to PCOS, menopause, and other key women’s health challenges.
- Continuous support: Participants will receive personalised care, including regular check-ins, comprehensive monitoring, and guidance from SheMed’s dedicated team.
Programme Extension
Due to overwhelming demand, SheMed has extended the trial’s duration to accommodate more participants while maintaining its rigorous standards. This extension allows SheMed to continue its mission of empowering women through evidence-based healthcare and contribute meaningful data to the medical community.
Participant Benefits
Participants will gain access to a wealth of support and resources, including:
- Tailored weight loss plans.
- Reduced risks of obesity-related complications such as heart disease and diabetes.
- Insights into the benefits of GLP-1s on conditions like PCOS and menopause.
- Complimentary blood collection kits at six and twelve months.
Data Privacy
SheMed is committed to protecting participants’ personal information. All data collected is anonymised and used solely for research purposes. SheMed does not sell or share any data with third parties.
Study Timeline
- Entry Period: Fall 2024
- Final Entry Date: January 31, 2025 (extended)
- Results will be released in 2026
Join the SheMed Clinical Trial
This extended timeline offers a unique opportunity for eligible participants to contribute to one of the largest women’s health studies in the UK. By joining the SheMed Weight Loss Programme, participants are not only investing in their health but also shaping the future of women’s healthcare.
Interested individuals can visit SheMed’s website to learn more about the programme and apply to join this landmark clinical study. With strict acceptance guidelines in place and limited slots available, early application is highly encouraged.
Sign up and check your eligibility today: https://www.shemed.co.uk/clinical-study